NEW YORK, August 4, 2026, 09:10 EDT
- At 8:58 EDT, shares changed hands at $0.4147. Premarket trading volume topped 80 million shares.
- The Nasdaq’s minimum 10-close compliance track must start by August 11.
Ensysce shares surged 48% in premarket trading, but the stock must climb an additional 141% to hit Nasdaq’s $1 minimum. Over 80 million shares changed hands ahead of the 9:30 a.m. market open.
The gap is significant, as Ensysce is required to log at least 10 qualifying closes by August 24. The earliest possible timeline commences on August 11. Nasdaq could require as many as 20 closes.
The 20-day continuous compliance window is now closed. A further compliance opportunity could remain, dependent on meeting additional listing criteria. Ensysce faces a distinct shortage in stockholders’ equity.
No new corporate announcements were posted Tuesday morning. The most recent update on Ensysce’s press-release site is dated July 14, and the filings list’s last entry is from July 15. The most recent 8-K disclosed the departure of Chief Operating Officer Jeffrey Millard.
The company announced the formal strategic review on May 15. At that time, the board stated it would explore partnerships as well as licensing options.
The chart illustrates how rapidly the surge subsided. Delayed quotes and trading volumes are listed below.
| Trading measure | Monday regular session | Monday after-hours | Tuesday premarket |
|---|---|---|---|
| Price | $0.2801 | $0.5691 | $0.4147 |
| Change from Monday close | — | +103.2% | +48.1% |
| Volume | 122.34 million | 121.44 million | 80.73 million |
| Quote time | 4:00 p.m. EDT | 7:59 p.m. EDT | 8:58 a.m. EDT |
The premarket quote was 27% lower than Monday’s after-hours pricing. However, premarket volume had already reached 18.6 times the 65-day average daily turnover.
The listing tests can be directly measured alongside each other. Ensysce’s equity attributable as of March 31 stood at negative $340,042.
| Nasdaq test | Latest disclosed measure | Requirement | Calculated gap |
|---|---|---|---|
| Minimum bid price | $0.4147 before market open | No less than $1.00 | Needs to increase 141.1% |
| Minimum qualifying streak | Most recent attempt: August 11 | Closes above threshold for 10 business days | Six sessions, counting Tuesday, needed to meet $1 |
| Stockholders’ equity | Deficit of $0.340 million | No lower than $2.5 million | $2.840 million below minimum, not yet considering future financing |
Ensysce stated it will file an equity-compliance plan by July 6. By Tuesday morning, its public filings did not include any further Nasdaq action.
The funding introduces a valuation complication. The $5.3 million award from the National Institute on Drug Abuse in July represents approximately 83% of a preliminary premarket equity valuation of $6.4 million. This calculation is based on 15.37 million shares and the 8:58 quote.
This comparison does not represent a cash-runway metric. Ensysce records grant revenue solely after eligible costs are incurred and determined to be reimbursable.
The most recent balance sheet on file highlights the importance of that distinction.
| Liquidity measure | Latest disclosed amount | Comparison |
|---|---|---|
| Cash and equivalents | $0.745 million as of March 31 | $4.310 million as of December 31; decline of 82.7% |
| First-quarter operating cash use | $3.501 million | $1.707 million in the previous year; an increase of 105% |
| April preferred financing | $2.0 million gross | 2,000 Series B preferred shares |
| July NIDA award | $5.3 million | 1.51 times greater than first-quarter operating cash use; cost-reimbursement funding |
CEO Lynn Kirkpatrick stated the funding enables Ensysce to “keep advancing MPAR.” The grant backs PF614-MPAR-102 and long-term nonclinical studies. Ensysce Biosciences, Inc.
On June 26, the company began the last phase of the study by enrolling its first patient. PF614-MPAR holds FDA Breakthrough Therapy status, though it is not yet approved.
According to the May update, PF614’s Phase 3 trial had enrolled 50% of its interim target. The board was evaluating partnership and licensing prospects.
Liquidity is still acting as a constraint. The May 10-Q indicated that existing resources would cover planned operations only until late June unless additional financing was obtained. That time frame has elapsed.
Risks: Ensysce could encounter delisting, experience dilution, require additional funding, or see delays and failures in clinical trials. Prices after hours are also volatile and can move dramatically.
The regular-session close on Tuesday carries greater significance than the premarket move. If shares finish near $0.42, both Nasdaq-related matters would stay unsettled.
